
PPADS tetrasodium
CAS No. 192575-19-2
PPADS tetrasodium ( —— )
产品货号. M33471 CAS No. 192575-19-2
PPADS tetrasodiuma 是一种非选择性 P2X 受体拮抗剂。PPADS tetrasodiuma 阻断重组P2X1、-2、-3、-5,IC50 范围为1~2.6 μM。PPADS-tetrasodiuma 阻断天然 P2Y2 样 (IC50~0.9 mM) 和重组 P2Y4 (IC50~15 mM) 受体。PPADS tetrasodiuma 是豚鼠气道平滑肌 Na/Ca2? 交换逆模式的抑制剂。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥568 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称PPADS tetrasodium
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述PPADS tetrasodiuma 是一种非选择性 P2X 受体拮抗剂。PPADS tetrasodiuma 阻断重组P2X1、-2、-3、-5,IC50 范围为1~2.6 μM。PPADS-tetrasodiuma 阻断天然 P2Y2 样 (IC50~0.9 mM) 和重组 P2Y4 (IC50~15 mM) 受体。PPADS tetrasodiuma 是豚鼠气道平滑肌 Na/Ca2? 交换逆模式的抑制剂。
-
产品描述PPADS tetrasodiuma is a non-selective P2X receptor antagonist. PPADS tetrasodiuma blocks recombinant P2X1, -2, -3, -5 with IC50s ranging from 1 to 2.6 μM. PPADS tetrasodiuma blocks native P2Y2-like (IC50~0.9 mM) and recombinant P2Y4 (IC50~15 mM) receptors. PPADS tetrasodiuma is an inhibitor of the reverse mode of the Na/Ca2+ exchanger in guinea pig airway smooth muscle.
-
体外实验PPADS tetrasodiuma (1-30 μM; 10-50 minutes) inhibits Na+/Ca2+ exchanger reverse mode (NCXREV) in a time- and concentration dependent manner.PPADS tetrasodiuma is effective at other native and recombinant P2XRs. At human P2XRs sensitivity to PPADS tetrasodiuma depended on the subtype and is highest at the hP2X1, -2, -3, -5, and -7Rs with an IC50 of ~1-3 and ~30 μM for the hP2X4R.
-
体内实验PPADS tetrasodiuma (15-60 mg/100g body weight (BW); i.p.; every 12 hoursfor 8 days) inhibits glomerular mesangial cells (MC) proliferation without altering proliferation of non-MC in vivo in mesangial proliferative glomerulonephritis.Animal Model:Male Sprague-Dawley ratsweighing 160 to 200 g (anti-Thy1 disease mode)Dosage:15 mg/100g BW, 30 mg/100g BW, 60 mg/100g BW Administration:i.p.; every 12 hours for 8 days (the first PPADS injection was administered 60 minutes after disease induction, and the loading dose always contained double the amount of PPADS compared to the following injections.)Result:Specifically and dose-dependently reduced early (day 3) glomerular mesangial cell proliferation without altering proliferation of non-MC.
-
同义词——
-
通路Membrane Transporter/Ion Channel
-
靶点P2X Receptor
-
受体P2X Receptor | Na+/Ca2+ Exchanger
-
研究领域——
-
适应症——
化学信息
-
CAS Number192575-19-2
-
分子量599.3
-
分子式C14H10N3Na4O12PS2
-
纯度>98% (HPLC)
-
溶解度In Vitro:?H2O 中的溶解度 : 50 mg/mL (83.43 mM; 超声助溶)
-
SMILESO=CC1=C(C(C)=NC(N=NC2=CC=C(S(=O)([O-])=O)C=C2S(=O)([O-])=O)=C1COP([O-])([O-])=O)O.[Na+].[Na+].[Na+].[Na+]
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Flores-Soto E, et al. PPADS, a P2X receptor antagonist, as a novel inhibitor of the reverse mode of the Na?/Ca2? exchanger in guinea pig airway smooth muscle. Eur J Pharmacol. 2012 Jan 15;674(2-3):439-44.?
产品手册




关联产品
-
Opiranserin hydrochl...
Opiranserin (VVZ-149) HydroHClide 是甘氨酸转运蛋白 2 型 (GlyT2) 和血清素受体 2A (5HT2A) 的双重拮抗剂,IC50 分别为 0.86 和 1.3 μM。它对 rP2X3 显示拮抗活性 (IC50=0.87 μM)。它正在开发为治疗术后疼痛的注射剂。
-
(E/Z)-Sivopixant
(E/Z)-Sivopixantis 是一种有效的 P2X3 受体拮抗剂,IC50 = 4 nM。 (E/Z)-Sivopixant 可用于呼吸系统疾病研究。
-
GSK-1482160
GSK-1482160 是一种可口服的 P2X7 受体负变构调节剂。P2X7 受体参与中枢和外周免疫细胞产生促炎细胞因子,例如 Il-1β。GSK-1482160 具有研究炎症性疾病的潜力。